KIT and melanoma: Somatic missense activating mutations in BRAF have been identified in about 60% of primary melanoma lesions (Davies et al, 2002), and KIT mutations in 14% and 18% of acral lentiginous and mucosal melanomas, respectively (Woodman and Davies, 2010).